SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

Rhea-AI Summary

SciSparc (Nasdaq: SPRC) said NeuroThera Labs (TSXV: NTLX), in which SciSparc holds a controlling interest of ~75%, advanced a collaboration with Clearmind via publication of a PCT international patent application for a MEAI–PEA combination targeting weight loss and MASLD.

The release cites global prevalence figures (obesity ~890 million adults; MASLD ~30% adults) and market estimates (weight loss drugs ~$37B in 2025, ~$226B by 2035).

Positive

• Controlling interest of ~75% in NeuroThera
• PCT patent publication for MEAI–PEA combination therapy
• Cites large addressable markets: obesity ~890M adults and MASLD ~30% adults

Negative

• None.

News Market Reaction – SPRC

+22.86% 2.9x vol

10 alerts

+22.86% News Effect

+14.7% Peak in 6 min

+$405K Valuation Impact

$2M Market Cap

2.9x Rel. Volume

On the day this news was published, SPRC gained 22.86%, reflecting a significant positive market reaction. Argus tracked a peak move of +14.7% during that session. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $405K to the company's valuation, bringing the market cap to $2M at that time. Trading volume was elevated at 2.9x the daily average, suggesting notable buying interest.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

NeuroThera ownership: approximately 75% Global obesity burden: over 890 million adults MASLD prevalence: approximately 30% +2 more

5 metrics

NeuroThera ownership approximately 75% SciSparc controlling interest in NeuroThera Labs

Global obesity burden over 890 million adults Adults affected by obesity worldwide

MASLD prevalence approximately 30% Share of global adult population with MASLD

Weight loss drugs market 2025 approximately $37 billion Global weight loss drugs market value in 2025

Weight loss drugs market 2035 $226 billion Forecast global weight loss drugs market by 2035

Market Reality Check

Price: $4.73 Vol: Volume 27,475 vs 20-day a...

low vol

$4.73 Last Close

Volume Volume 27,475 vs 20-day average 73,690 (relative volume 0.37x), indicating lighter-than-usual trading ahead of this announcement. low

Technical Shares at $3.85, trading below the 200-day moving average of $31.86 and only modestly above the $3.6001 52-week low, far from the $94.5 high.

Peers on Argus

Pre-news scanner data shows only one peer (ELAB) in momentum, moving down, while...

1 Down

Pre-news scanner data shows only one peer (ELAB) in momentum, moving down, while broader biotech peers show mixed moves (+8.91% PTIX vs -29.14% UBX). This points to stock-specific factors rather than a clear sector-wide pattern.

Previous Partnership Reports

1 past event · Latest: Nov 20 (Positive)

Same Type Pattern 1 events

Date	Event	Sentiment	Move	Catalyst
Nov 20	Partnership patent filing	Positive	-4.5%	Israeli patent application with Clearmind for MEAI‑PEA combination targeting depression.

Pattern Detected

For similar Clearmind/NeuroThera partnership IP news, the stock previously moved negatively despite constructive collaboration and patent developments.

Recent Company History

Recent months show SciSparc pursuing IP- and deal-heavy growth: multiple acquisitions of endoscopy-related IP in Jan 2026, cannabinoid-antimicrobial patent news on Feb 2, 2026, a reverse share split announced on Mar 2, 2026, and a CliniQuantum acquisition agreement on Mar 10, 2026. Today’s partnership news extends the NeuroThera–Clearmind IP strategy into obesity and MASLD, building on earlier MEAI/PEA collaboration for depression.

Historical Comparison

-4.5% avg move · Past Clearmind–NeuroThera partnership news around MEAI‑based therapies produced an average -4.47% mo...

partnership

-4.5%

Average Historical Move partnership

Past Clearmind–NeuroThera partnership news around MEAI‑based therapies produced an average -4.47% move, showing that collaborative IP milestones have not historically translated into positive short-term trading for SPRC.

Partnership news has progressed from an Israeli patent application for MEAI‑PEA in depression to an international PCT application expanding the same platform toward obesity and MASLD, indicating an IP build-out across multiple CNS and metabolic indications.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2026-02-17

An active Form F-3 dated Feb 17, 2026 registers up to 23,037,624 ordinary shares for resale by existing investors, tied to convertible notes and warrants. The filing highlights potential dilution, resale overhang, share-price volatility, Nasdaq equity-compliance challenges, and prior going-concern language, all of which frame additional risk around equity-linked funding.

Market Pulse Summary

The stock surged +22.9% in the session following this news. A strong positive reaction aligns with S...

Analysis

The stock surged +22.9% in the session following this news. A strong positive reaction aligns with SciSparc’s strategy of leveraging NeuroThera’s MEAI‑PEA platform and prior Clearmind collaborations. Investors have previously seen partnership IP news around this platform, with an average move of -4.47%, so a sharp gain would mark a departure from that pattern. Resale registration for up to 23,037,624 shares and convertible note structures could still weigh on durability of any rally.

Key Terms

patent cooperation treaty (pct), metabolic dysfunction-associated steatotic liver disease (masld), masld, neuroplastogen, +2 more

6 terms

patent cooperation treaty (pct) regulatory

"publication of an international patent application under the Patent Cooperation Treaty (PCT)"

An international patent filing system that lets an applicant start the patent process in many countries with a single unified application, like submitting one passport-style request instead of separate applications for each country. It matters to investors because PCT filings can preserve and coordinate intellectual property rights globally while a company refines its markets and partners; a robust PCT strategy can protect future revenue streams, signal competitive advantage, and affect valuation and licensing potential.

metabolic dysfunction-associated steatotic liver disease (masld) medical

"metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as fatty liver disease)"

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a chronic liver condition where excess fat builds up in the liver because of underlying metabolic problems such as obesity, insulin resistance, or high blood lipids. Investors should care because MASLD represents a large and growing patient population that drives demand for diagnostics, treatments, and monitoring services; think of it as a widespread maintenance issue that creates ongoing market opportunities across healthcare and pharmaceuticals.

masld medical

"weight loss and metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as fatty liver disease)"

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a chronic condition where excess fat builds up in the liver due to underlying metabolic problems like insulin resistance, obesity, or high blood lipids. Think of the liver like a kitchen filter getting clogged with grease; over time that buildup can reduce function and lead to inflammation or scarring, which matters to investors because it signals a large, growing market for diagnostics, treatments, and related medical services.

neuroplastogen medical

"offer a safe, non-hallucinogenic neuroplastogen treatment for two major global health challenges"

A neuroplastogen is a drug or compound designed to boost the brain’s ability to rewire and form new connections, enhancing recovery or adaptation after injury, stress, or disease. For investors, these molecules matter because they target underlying brain repair processes rather than just masking symptoms, offering the potential for durable benefits in conditions like depression, neurodegeneration, or cognitive decline—akin to giving a tired garden fresh tools to regrow and reshape itself.

central nervous system (cns) medical

"clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system (CNS) disorders"

The central nervous system (CNS) is the part of the body that includes the brain and spinal cord, acting as the control center for processing information and directing actions. It is essential for coordinating all bodily functions, from movement to thinking. For investors, understanding the CNS is important because it illustrates how complex systems—like markets or organizations—rely on core components to operate smoothly.

glp-1s agonists medical

"more cost effective option than GLP-1s agonists for obesity and MASLD"

GLP‑1 agonists are medicines that mimic a natural gut hormone to help the body release insulin and reduce appetite, often producing meaningful blood‑sugar control and weight loss. They matter to investors because their clinical benefits can drive large sales, reshape markets for diabetes and obesity treatments, and create winners and losers across drugmakers, insurers and suppliers — much like a popular new smartphone can shift an entire tech industry.

AI-generated analysis. Not financial advice.

TEL AVIV, Israel, March 12, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system (CNS) disorders, in which SciSparc holds a controlling interest of approximately 75%, has advanced its collaboration with Clearmind Medicine Inc. with the publication of an international patent application under the Patent Cooperation Treaty (PCT) for a novel combination therapy aimed at treating weight loss and metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as fatty liver disease).

The patent publication highlights the potential of a  5-methoxy-2-aminoindane (MEAI)-Palmitoylethanolamide (PEA) combination to offer a safe, non-hallucinogenic neuroplastogen treatment for two major global health challenges: obesity, affecting over 890 million adults worldwide, and MASLD, impacting approximately 30% of the global adult population. Moreover, due to the presumed mechanism of action of the combination, this therapeutic option may offer a safer, easier and more cost effective option than GLP-1s agonists for obesity and MASLD.

By combining Clearmind’s MEAI platform with NeuroThera’s PEA, the companies wish to address the escalating demand for effective, tolerable and safe treatments in the obesity and liver health space. This comes at a time when the global weight loss drugs market is experiencing rapid growth, which was valued at approximately $37 billion in 2025 and is forecasted to reach $226 billion by 2035, driven by increasing awareness of obesity as a chronic disease and the need for innovative alternatives to GLP-1 agonists.

About SciSparc Ltd. (Nasdaq: SPRC):

The Company, through its majority-owned subsidiary NeuroThera Labs Inc., engages in clinical-stage pharmaceutical developments. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, together with its majority-owned subsidiary NeuroThera Labs Inc., are currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer's disease and agitation; and SCI- 210 for the treatment of ASD and status epilepticus. The Company, through NeuroThera Labs Inc., also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace.

About NeuroThera Labs Inc.

NeuroThera Labs Inc. is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc uses forward-looking statements when it discusses the potential benefits and advantages of the potential therapeutic benefits of the MEAI-PEA combination for the treatment of obesity and MASLD; the potential for the MEAI-PEA combination to offer a safer, easier, and more cost-effective alternative to GLP-1 agonists; the presumed mechanism of action of the combination therapy; the anticipated demand for novel treatments in the obesity and liver health space; projections regarding the growth and future value of the global weight loss drugs market; and the Company's ability to advance the collaboration with Clearmind Medicine Inc. and develop the combination therapy toward commercialization. Because such statements deal with future events and are based on SciSparc's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in SciSparc's Annual Report on Form 20-F, as amended, filed with the SEC on April 24, 2025, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055

FAQ

What did SciSparc (SPRC) announce on March 12, 2026 about NeuroThera and Clearmind?

SciSparc announced publication of an international PCT patent application for a MEAI–PEA combination therapy. According to the company, the collaboration advances a non‑hallucinogenic neuroplastogen approach targeting obesity and MASLD.

How much of NeuroThera does SciSparc (SPRC) control after the collaboration announcement?

SciSparc holds a controlling interest of approximately 75% in NeuroThera. According to the company, that stake underpins SciSparc's strategic exposure to the MEAI–PEA development program moving forward.

What clinical targets does the MEAI–PEA patent published by SciSparc (SPRC) pursue?

The patent targets weight loss and metabolic dysfunction‑associated steatotic liver disease (MASLD). According to the company, the combination aims to offer a safe, non‑hallucinogenic neuroplastogen treatment option for both conditions.

What market opportunity did SciSparc (SPRC) cite for the weight loss drugs sector?

The company cited a global weight loss drugs market valued at about $37 billion in 2025 and forecast to reach $226 billion by 2035. According to the company, growth is driven by chronic disease recognition and demand for alternatives to GLP‑1s.

Does the patent publication mean imminent regulatory approval for SciSparc's (SPRC) therapy?

No, a PCT patent publication secures intellectual property filing but is not regulatory approval. According to the company, the publication protects the MEAI–PEA concept while clinical and regulatory steps remain ongoing.